DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Zanolimumab
Zanolimumab
Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
Modifications to the Harmonized Tariff Schedule of the United States To
Foxp3 T Cells Inhibit Antitumor Immune Memory Modulated By
Newer Monoclonal Antibodies for Hematological Malignancies
Ep 3178848 A1
The Role of Monoclonal Antibodies in the Management of Leukemia
International Nonproprietary Names for Pharmaceutical Substances (INN)
Assessment Report
INN Working Document 05.179 Update 2011
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
International Nonproprietary Names for Pharmaceutical Substances (INN)
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
A Free F1-Remicade F1-Renicade
New Strategies in Peripheral T-Cell Lymphoma: Understanding Tumor Biology and Developing Novel Therapies
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
Patent No.: US 8877913 B2
Top View
Positive Public Summary of Opinion
Novel Antibodies in the Treatment of Non-Hodgkin's Lymphoma
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Genmab to Present Zanolimumab and Ofatumumab Data at Ash
Treatment and Clinical Trials for PTCL
Customs Tariff - Schedule
1 1 RISK FACTORS an Investment in Genmab's Shares, Including Any New Shares, Involves a High Degree of Risk. in Addition to Th
Assessment of the Evolution of Cancer Treatment Therapies
The Current State and the Issues of Antibody Drugs
The Time to Target and Terminate the Threat of Ptcl
Customs Tariff - Schedule Xxi - 1
Phase II Trial of Zanolimumab (Humax-CD4) in Relapsed Or Refractory Non-Cutaneous Peripheral T-Cell Lymphoma
Activated B-Cell
Hematology Drugs in the Pipeline
I Nuovi Anticorpi Anti-Linfoma
Immunomodulatory Treatment for the Intractable Paediatric Epilepsies Luis E
Cellular, Tissue, and Gene Therapies Advisory Committee Curriculum Vitae Bernard A
(INN) for Biological and Biotechnological Substances
Zanolimumab (Humax-CD4®), a Fully Human Monoclonal Antibody in Clinical Development for Cutaneous T-Cell Lymphoma
Thalidomide - Wikipedia, the Free Encyclopedia
A Human CD4 Monoclonal Antibody for the Treatment of T-Cell Lymphoma Combines Inhibition of T-Cell Signaling by a Dual Mechanism
Monoclonal Antibodies a New Frontier in Treating Rheumatoid Arthritis
Assessment of the Evolution of Cancer Treatment Therapies
International Nonproprietary Names (INN) for Biological and Biotechnological Substances